BioSpace News Archive

Key presentations, including new analyses, highlight NURTEC clinical benefits including rapid and sustained efficacy with a single dose, low rescue medication use, long-term safety in patients with cardiovascular risk factors and concomitant preventive migraine medications

Bausch Health Companies Inc. announced that Paul S. Herendeen, executive vice president and chief financial officer, Arthur J. Shannon, senior vice president and head of Investor Relations and Communications, and William Woodfield, vice president and treasurer, are scheduled to participate at the virtual Goldman Sachs Leveraged Finance Conference on June 25, 2020, at 11:25 a.m. EDT.

Phase 2 Trial with Bavituximab in Patients with Gastric Cancer on Track to Report Preliminary Results During the Second Half of 2020

The World Economic Forum announced its selection of 100 of the most promising Technology Pioneers of 2020, which are shaping industries from agriculture to healthcare while also working on sustainability issues and much more.

Today, Abiomed (NASDAQ: ABMD) launches a cutting-edge digital education platform called CAMP PCI , which stands for Coronary Artery & Myocardial Protected Percutaneous Coronary Intervention, to improve patient outcomes and quality of life with supported high-risk PCI by utilizing best practices, techniques and technologies to enable safer, more effective and complete revascularization. The launch of the platform, o

Vyome Therapeutics, a clinical-stage company developing locally-acting, next generation therapeutics for immuno-inflammatory diseases, today announced positive data from its Phase 2 trial of VB-1953, a first-in-class topical bactericidal and TLR-MD2 inhibitor being developed for the treatment of moderate to severe inflammatory facial acne vulgaris. Results from the trial demonstrated a statistically significant difference in the primary endp

Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update about the Company’s business at the BMO 2020 Prescriptions for Success Healthcare Conference.

Keystone Heart, LTD., a medical device innovator driven to redefine the standard of structural heart care, announced it has acquired 510 Kardiac Devices, Inc., a privately-held medical device company and makers of the Lim Transseptal System.

CyMedica completes early enrollment and launches rollover study of a clinical trial to evaluate the effectiveness of e-vive for reducing pain and improving function by increasing quadriceps strength in knee osteoarthritis patients. [16-June-2020] SCOTTSDALE, Ariz. , June 16, 2020 /PRNewswire/ -- CyMedica Orthopedics®, the leading combined muscle strengthening therapy

Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Stéphane Bancel, Chief Executive Officer, will participate virtually in the BMO 2020 Prescriptions for Success Healthcare Conference on June 23 rd at 3:00 p.m. ET. A live webcast will be available und